key: cord-1010356-zqqon9ra authors: Mejía-Parra, Jorge Luis; Aguilar-Martinez, Sergio; Fernández-Mogollón, Jorge Luis; Luna, Camila; Bonilla-Aldana, D. Katterine; Rodriguez-Morales, Alfonso J.; Diaz-Velez, Cristian title: Characteristics of patients coinfected with Severe Acute Respiratory Syndrome Coronavirus 2 and dengue virus, lambayeque, Peru, May–August 2020: A retrospective analysis date: 2021-06-26 journal: Travel Med Infect Dis DOI: 10.1016/j.tmaid.2021.102132 sha: 68392aeb4339a4be491d56813c5eeace93557084 doc_id: 1010356 cord_uid: zqqon9ra INTRODUCTION: Before the Coronavirus Disease 2019 (COVID-19) arrival and its pandemic, dengue was already a significant cause of epidemics in South East Asia and Latin America. In 2020 with their cocirculation, coinfections began to be observed and reported in different countries. As expected, this syndemic is evident in different areas and deserves proper characterisation and studies in Peru. METHODS: We retrospectively assessed the clinical, epidemiological, diagnostic characteristics and outcomes in a Social Security Hospital of Chiclayo, Lambayeque, Peru, of patients that were diagnosed simultaneously with COVID-19 and dengue during May–August 2020. RESULTS: A total of 50 patients with COVID-19/dengue coinfection were identified. Of them, 60% presented thrombocytopenia, and 52% fever, among other findings. The case fatality rate in this group was 28%, being higher in those patients initially classified as severe dengue (100%), as well as in females (55%) than males (21%) (OR = 4.65; 95%CI 1.18–18.45). DISCUSSION: Co-occurrence of COVID-19/Dengue is growing as a consequence of the syndemic of these viral diseases in endemic areas, such as Latin America, and as both conditions may evolve to severe disease, their epidemiological but clinical interaction in terms of outcomes need further assessment in future studies in the region. Before the pandemic of Coronavirus Disease 2019 , caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), epidemics of different arbovirus have been affecting significantly Asia-Pacific and Latin American regions in a significant way over the last decade [1, 2] . Dengue persists as the central viral disease transmitted by vectors such as Aedes aegypti in such regions [3, 4] . Latin America has been one of the most significantly affected regions by COVID-19 [5] , including Peru [6] . Therefore, as soon as COVID-19 arrived in Latin America, multiple implications were expected, considering the regional epidemiology of endemic diseases such as dengue [7] [8] [9] , especially in Brazil [8] , Colombia [10] , Ecuador [9] and Peru [11] , among others. Dengue and COVID-19 share clinical findings, such as fever, myalgia, fatigue, headache, rash [12] , and laboratory findings, making, in endemic areas or in travellers coming from, difficult to distinguish between both conditions. Additionally, as expected, coinfections COVID-19/Dengue have been reported in different countries, such as Mayotte (Indian ocean) [13] , La Reunión (Indian ocean) [14] , Argentina [15] [16] [17] , Colombia [18] , among others. Then, although COVID-19/Dengue coinfection is becoming a significant concern [17] , only individual case reports [13] [14] [15] [16] and one 13-patient cohort [17] have been described in the literature. Therefore, we report the clinical characteristics and outcomes in a cohort of patients co-infected with SARS-CoV-2 and Dengue virus in Chiclayo, Lambayeque department, Peru. SARS-CoV-2 was diagnosed using real-time PCR of nasopharyngeal swab specimens or serological tests detecting IgM/IgG antibodies against SARS-CoV-2, as approved by the Ministry of Health in reference laboratories. Dengue was diagnosed by either detection of non-structural protein 1 (NS1) (for patients with less than five days of symptoms) or serological tests detecting IgM/IgG (for patients with symptoms more significant than five days). Real-time PCR for Dengue is not regularly used for diagnosis. We included all the patients diagnosed simultaneously with COVID-19 and Dengue, or that said coinfection was after two weeks or more of the diagnosis of COVID-19. Hospitalised patients in the COVID-19 area of a Social Security Level III Hospital and patients followed up by telephone during May-August 2020 were included. Patients were included after detecting the Aedes aegypti vector after undergoing entomological surveillance of evolutionary forms such as eggs, larvae and adults, within the hospital environment. This finding motivated us to review the medical records of hospitalised patients in the COVID-19 area. The following were considered criteria for suspicion of dengue infection [19, 20] : Patients with a temperature greater than 38°C for 2 to 3 J o u r n a l P r e -p r o o f consecutive days, after having received anti-inflammatory and antipyretic treatment for COVID-19 infection, control blood count with thrombocytopenia (<150,000 platelets/mL) and increased haematocrit, patients with arthralgia in hands and feet, retro-ocular pain, headache, low back pain, persistent abdominal pain, hypothermia, drowsiness and petechiae in the extremities and abdomen [19, 20] . For this study, the case fatality (CFR%) rate was defined as the proportion of cases that died (CFR%=deaths/cases x100). The criteria for the classification of Dengue cases (Dengue without warning signs, dengue with warning signs, and Dengue Severe) were applied according to the clinical practice guidelines for dengue cases in Peru and the recommendations of the WHO [20] . Therefore, this study was waived of Ethics Committee approval, as is a retrospective analysis. A total of 50 patients who had coinfections with SARS-CoV-2 and Dengue virus were identified. Most patients were relatively young (median age 55.5 years, interquartile range 40.5-65, minimum 15, maximum 89), 78% were male (Table 1) . Most patients had thrombocytopenia (60%, n=30), and 52% (n=26) had febrile disease at diagnosis (median temperature of 38.1°C), among other clinical findings (Table 2 ). Rash appeared in 3 patients early in the disease and before the resolution of fever (Table 2) . Of the total, 32% (n=16) presented hypertension and type 2 diabetes mellitus (26%, n=18), among other comorbidities ( Antigen-DENV (54%, n=27), followed by SARS-CoV-2 IgM/IgG Rapid Test and DENV IgM/IgG Antibodies (38%, n=19), RT-PCR for SARS-CoV-2 and NS1 Antigen-DENV (6%, n=3), and RT-PCR for SARS-CoV-2 and DENV IgM/IgG Antibodies (2%, n=1), none (0%) by IgG (Table 3) . Of the 50 cases, 6% (n=3) developed severe dengue (which were admitted to the intensive care unit [ICU]), 58% (n=29) Dengue with warning signs, and 36% (n=18) Dengue without warning signs (Table 2) . Of the total, 76% (n=38) of the patients presented COVID-19 pneumonia. The case fatality rate (CFR%) in the group was 28% (n=14) ( Table 4 ). All the patients with severe dengue died (100%, n=3), whilst that occurred in 28% (n=8) of those that developed warning signs and 17% (n=3) of those without warning signs ( Table 4 ). The case fatality rate was higher in females (55%, n=6) than males (21%, n=8) (OR=4.65; 95%CI 1.18-18.45) ( Table 5 ). December 31, 2019, marked the beginning of an epidemic that evolved up to a pandemic that has lasted more than a year since the first cases reported in Wuhan, Hubei province, China [21] [22] [23] [24] . Latin America has been one of the most significantly affected regions by COVID-19 [5] . Multiple threats have been progressively growing with the interaction between COVID-19 and other infectious and non-infectious conditions in this region as in others. However, with the epidemiological overlapping in the tropics, the menace of COVID-19 and Dengue and potentially for other arboviral and tropical diseases is more a real additional burden during the ongoing pandemic [10] . An Besides, Lambayeque has reported more than 36,000 confirmed cases of COVID-19 in this department [25] . At the same time, these areas are historically endemic for dengue. Then, among the multiple implications, multiple factors suggest the risk that both may lead to severe disease simultaneously. Both viral diseases may trigger secondary hemophagocytic lymphohistiocytosis [26] [27] [28] , leading patients to present hypovolemic shock, vasoplegia, and cardiopulmonary collapse due to hyperinflammation and hyperactivation of the immune system. However, this was not explicitly observed in this cohort from Peru [29] . So far, no severe COVID-19/Dengue was reported in previous studies, nor required admission to an intensive care unit, or died during follow up [13] [14] [15] [16] [17] . However, in Peru, at this cohort of COVID-19/Dengue coinfected patients, the largest until now, 28% of them died, which is usually higher than the CFR for mono-infection due to SARS-CoV-2 [30] , as well as for Dengue [3] . At the same time, some studies indicated that the CFR for dengue in north Peru is relevant, and high as 1.3 per 1,000 cases in Piura and 9.3 per 1,000 in Lambayeque, where is Chiclayo located [31] . In Brazil, it is often observed that the number of dengue cases increases at the beginning of the year due to the rainy season and high temperatures and peaks between March and April. Meanwhile, the peak of the COVID-19 outbreak in Brazil is forecast to occur in the winter season, when respiratory illnesses are found most frequently. This temporal coincidence implies that the two outbreaks can occur at the same time [8] . Thus, we have that in some cities in Brazil, it was observed that states in which a significant fraction of the population had contracted dengue fever in 2019-2020 reported fewer cases and deaths from COVID-19, and took longer to achieve exponential community transmission because the growth rates of SARS-CoV-2 infection are slower. This inverse correlation between COVID-19 and Dengue was observed in a sample of countries in Asia and Latin America and islands in the Pacific and Indian oceans [39] . On the other hand, a recent report described two cases of patients diagnosed with dengue by rapid test, false positives, due to a cross-reaction of the IgM and IgG antibodies SARS-CoV-2 [36] . Similarly, another report warns of a possible antibodydependent enhancement (ADE), as they speculate that neutralising antibodies (Nab) against the RBD region of protein S (Spike) could favour the entry of SARS-CoV-2 to host cells and therefore increase viremia, thus, a worsening of the condition of patients with COVID-19 disease [40] . In Ecuador, some data found that most of the febrile Dengue cases would overlap the cases of COVID-19 because they share similar clinical characteristics [9] . In Brazil, some authors have warned that the coinfection of Dengue and COVID-19 could cooccur, especially from June to September [8] . Our hospital in Lambayeque, Peru, demonstrated that this coinfection is occurring with its clinical implications. This study is the first coinfection assessment in Peru, as well as the largest in Latin America. Although many limitations may be highlighted, we can observe the main clinical features and outcomes associated. Many questions may be raised in this context, including if dengue is a risk factor for severe COVID-19 and a worse outcome in patients without coinfection than those only presenting COVID-19 or Dengue. We should acknowledge that although 40% of the dengue cases infection were not diagnosed by RT-PCR or NS1 antigen, it is essential to emphasise that IgM diagnosed 38% of them, suggesting acute infection and not a past infection 2% by IgM/IgG and 0% by IgG. Nevertheless, the recommendation for COVID-19/Dengue coinfection is to use RT-PCR for SARS-CoV-2 and dengue viruses [18] . As this was a retrospective study, no other coinfections were initially assessed. other potential confounding factors, such as the use of antipyretics and antiinflammatory agents, should be considered to explain why the fever was only detected in around half of the cases. When suspecting coinfections [37] [38] [39] [40] , other arboviruses are important to performed RT-PCR, as not only with serological antibody testing crossreactivity has been reported, also with NS1 antigen testing [41] , but still is not clear how substantial is this cross-reactivity and its magnitude. None. Approval was not required. All authors report no potential conflicts. 26 J o u r n a l P r e -p r o o f [3, 4] . Latin America has been one of the most significantly affected regions by COVID-19 [5] , including Peru [6] . Therefore, as soon as COVID-19 arrived in Latin America, multiple implications were expected, considering the regional epidemiology of endemic diseases such as dengue [7] [8] [9] , especially in Brazil [8] , Colombia [10] , Ecuador [9] and Peru [11] , among others. Dengue and COVID-19 share clinical findings, such as fever, myalgia, fatigue, headache, rash [12] , and laboratory findings, making, in endemic areas or in travellers coming from, difficult to distinguish between both conditions. Additionally, as expected, coinfections COVID-19/Dengue have been reported in different countries, such as Mayotte (Indian ocean) [13] , La Reunión (Indian ocean) [14] , Argentina [15] [16] [17] , Colombia [18] , among others. Then, although COVID-19/Dengue coinfection is becoming a significant concern [17], only individual case reports [13] [14] [15] [16] and one 13-patient cohort [17] have been described We included all the patients diagnosed simultaneously with COVID-19 and Dengue, or that said coinfection was after two weeks or more of the diagnosis of COVID-19. Hospitalised patients in the COVID-19 area of a Social Security Level III Hospital and patients followed up by telephone during May-August 2020 were included. Patients were included after detecting the Aedes aegypti vector after undergoing entomological surveillance of evolutionary forms such as eggs, larvae and adults, within the hospital environment. This finding motivated us to review the medical records of hospitalised patients in the COVID-19 area. The following were considered criteria for suspicion of dengue infection [19, 20] : Patients with a temperature greater than 38°C for 2 to 3 J o u r n a l P r e -p r o o f consecutive days, after having received anti-inflammatory and antipyretic treatment for COVID-19 infection, control blood count with thrombocytopenia (<150,000 platelets/mL) and increased haematocrit, patients with arthralgia in hands and feet, retro-ocular pain, headache, low back pain, persistent abdominal pain, hypothermia, drowsiness and petechiae in the extremities and abdomen [19, 20] . For this study, the case fatality (CFR%) rate was defined as the proportion of cases that died (CFR%=deaths/cases x100). The criteria for the classification of Dengue cases (Dengue without warning signs, dengue with warning signs, and Dengue Severe) were applied according to the clinical practice guidelines for dengue cases in Peru and the recommendations of the WHO [20] . Therefore, this study was waived of Ethics Committee approval, as is a retrospective analysis. From the total, 76% (n=38) required hospitalization ( Table 1) . Diagnosis of COVID- Antigen-DENV (54%, n=27), followed by SARS-CoV-2 IgM/IgG Rapid Test and DENV IgM/IgG Antibodies (38%, n=19), RT-PCR for SARS-CoV-2 and NS1 Antigen-DENV (6%, n=3), and RT-PCR for SARS-CoV-2 and DENV IgM/IgG Antibodies (2%, n=1), none (0%) by IgG (Table 3) . Of the 50 cases, 6% (n=3) developed severe dengue (which were admitted to the intensive care unit [ICU]), 58% (n=29) Dengue with warning signs, and 36% (n=18) Dengue without warning signs ( Table 2) . Of the total, 76% (n=38) of the patients presented COVID-19 pneumonia. The case fatality rate (CFR%) in the group was 28% (n=14) ( Table 4 ). All the patients with severe dengue died (100%, n=3), whilst that occurred in 28% (n=8) of those that developed warning signs and 17% (n=3) of those without warning signs ( Table 4 ). The case fatality rate was higher in females (55%, n=6) than males (21%, n=8) (OR=4.65; 95%CI 1.18-18.45) ( Table 5 ). December 31, 2019, marked the beginning of an epidemic that evolved up to a pandemic that has lasted more than a year since the first cases reported in Wuhan, Hubei province, China [21] [22] [23] [24] . Latin America has been one of the most significantly affected regions by COVID-19 [5] . Besides, Lambayeque has reported more than 36,000 confirmed cases of COVID-19 in this department [25] . At the same time, these areas are historically endemic for dengue. Then, among the multiple implications, multiple factors suggest the risk that both may lead to severe disease simultaneously. Both viral diseases may trigger secondary hemophagocytic lymphohistiocytosis [26] [27] [28] , leading patients to present hypovolemic shock, vasoplegia, and cardiopulmonary collapse due to hyperinflammation and hyperactivation of the immune system. However, this was not explicitly observed in this cohort from Peru [29] . So far, no severe COVID-19/Dengue was reported in previous studies, nor required admission to an intensive care unit, or died during follow up [13] [14] [15] [16] [17] . However, in Peru, at this cohort of COVID-19/Dengue coinfected patients, the largest until now, 28% of them died, which is usually higher than the CFR for mono-infection due to SARS-CoV-2 [30] , as well as for Dengue [3] . At the same time, some studies indicated that the CFR for dengue in north Peru is relevant, and high as 1.3 per 1,000 cases in Piura and 9.3 per 1,000 in Lambayeque, where is Chiclayo located [31] . In Brazil, it is often observed that the number of dengue cases increases at the beginning of the year due to the rainy season and high temperatures and peaks between March and April. Meanwhile, the peak of the COVID-19 outbreak in Brazil is forecast to occur in the winter season, when respiratory illnesses are found most frequently. This temporal coincidence implies that the two outbreaks can occur at the same time [8] . Thus, we have that in some cities in Brazil, it was observed that states in which a significant fraction of the population had contracted dengue fever in 2019-2020 reported fewer cases and deaths from COVID-19, and took longer to achieve exponential community transmission because the growth rates of SARS-CoV-2 infection are slower. This inverse correlation between COVID-19 and Dengue was observed in a sample of countries in Asia and Latin America and islands in the Pacific and Indian oceans [39] . On the other hand, a recent report described two cases of patients diagnosed with dengue by rapid test, false positives, due to a cross-reaction of the IgM and IgG antibodies SARS-CoV-2 [36] . Similarly, another report warns of a possible antibodydependent enhancement (ADE), as they speculate that neutralising antibodies (Nab) against the RBD region of protein S (Spike) could favour the entry of SARS-CoV-2 to host cells and therefore increase viremia, thus, a worsening of the condition of patients with COVID-19 disease [40] . In Ecuador, some data found that most of the febrile Dengue cases would overlap the cases of COVID-19 because they share similar clinical characteristics [9] . In Brazil, some authors have warned that the coinfection of Dengue and COVID-19 could cooccur, especially from June to September [8] . This study is the first coinfection assessment in Peru, as well as the largest in Latin America. Although many limitations may be highlighted, we can observe the main clinical features and outcomes associated. Many questions may be raised in this context, including if dengue is a risk factor for severe COVID-19 and a worse outcome in patients without coinfection than those only presenting COVID-19 or Dengue. We should acknowledge that although 40% of the dengue cases infection were not diagnosed by RT-PCR or NS1 antigen, it is essential to emphasise that IgM diagnosed 38% of them, suggesting acute infection and not a past infection 2% by IgM/IgG and 0% by IgG. Nevertheless, the recommendation for COVID-19/Dengue coinfection is to use RT-PCR for SARS-CoV-2 and dengue viruses [18] . As this was a retrospective study, no other coinfections were initially assessed. in around half of the cases. When suspecting coinfections [37] [38] [39] [40] , other arboviruses are important to performed RT-PCR, as not only with serological antibody testing crossreactivity has been reported, also with NS1 antigen testing [41] , but still is not clear how substantial is this cross-reactivity and its magnitude. None. Approval was not required. All authors report no potential conflicts. J o u r n a l P r e -p r o o f The arboviral burden of disease caused by co-circulation and co-infection of dengue, chikungunya and Zika in the Americas Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America Dengue in Honduras and the Americas: The epidemics are back Spatial distribution of dengue in Honduras during 2016-2019 using a geographic information systems (GIS)-Dengue epidemic implications for public health and travel medicine COVID-19 in Latin America: The implications of the first confirmed case in Brazil Preparación y control de la enfermedad por coronavirus 2019 (COVID-19) en América Latina Actualización de alerta epidemiológica ante el riesgo de introducción del COVID-19, en el Perú COVID-19 and dengue fever: A dangerous combination for the health system in Brazil COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained health care systems over the edge Dengue and COVID-19, overlapping epidemics? An analysis from Colombia COVID-19 and dengue: Pushing the peruvian health care system over the edge COVID-19 can present with a rash and be mistaken for dengue": Petechial rash in a patient with COVID-19 infection COVID-19 and dengue co-infection in a returning traveller Co-infection of dengue and COVID-19: A case report SARS-CoV-2 and Dengue virus Coinfection. A Case Report Characteristics of Patients Co-infected with Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus SARS-CoV-2 and Dengue virus co-infection: a case from North Caribbean Colombia Caracterización clínica y de laboratorio en pacientes pediátricos en la etapa crítica del dengue Guía de Práctica Clínica para la Atención de Casos de Dengue en el Perú Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment A Novel Coronavirus from Patients with Pneumonia in China Coronavirus Disease 2019-COVID SARS-CoV-2 seroprevalence study in The arboviral burden of disease caused by co-circulation and co-infection of dengue, chikungunya and Zika in the Americas Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America Dengue in Honduras and the Americas: The epidemics are back Spatial distribution of dengue in Honduras during 2016-2019 using a geographic information systems (GIS)-Dengue epidemic implications for public health and travel medicine COVID-19 in Latin America: The implications of the first confirmed case in Brazil Preparación y control de la enfermedad por coronavirus 2019 (COVID-19) en América Latina Actualización de alerta epidemiológica ante el riesgo de introducción del COVID-19, en el Perú COVID-19 and dengue fever: A dangerous combination for the health system in Brazil COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained health care systems over the edge Dengue and COVID-19, overlapping epidemics? An analysis from Colombia COVID-19 and dengue: Pushing the peruvian health care system over the edge COVID-19 can present with a rash and be mistaken for dengue": Petechial rash in a patient with COVID-19 infection COVID-19 and dengue co-infection in a returning traveller Co-infection of dengue and COVID-19: A case report SARS-CoV-2 and Dengue virus Coinfection. A Case Report Characteristics of Patients Co-infected with Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus SARS-CoV-2 and Dengue virus co-infection: a case from North Caribbean Colombia Caracterización clínica y de laboratorio en pacientes pediátricos en la etapa crítica del dengue Guía de Práctica Clínica para la Atención de Casos de Dengue en el Perú Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment A Novel Coronavirus from Patients with Pneumonia in China Coronavirus Disease 2019-COVID SARS-CoV-2 seroprevalence study in Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review Severe dengue due to secondary hemophagocytic lymphohistiocytosis: A case study Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis Coinfection between dengue and covid-19: need for approach in endemic zones Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis Letalidad por dengue en centros asistenciales del Seguro Social de Perú durante El Niño Costero Dengue-COVID-19 coinfection: the first reported case in the Philippines. Western Pacific surveillance and response journal : WPSAR The impact of COVID-19 lockdown on dengue transmission in Sri Lanka; A natural experiment for understanding the influence of human mobility Dengue and COVID-19: A risk of coepidemic in Ethiopia Impact of sars-cov-2 interventions on dengue transmission Covert COVID-19 and false-positive dengue serology in Singapore Serological cross-reaction and coinfection of dengue and COVID-19 in Asia: Experience from Indonesia Low risk of serological cross-reactivity between dengue and COVID-19 How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective Evaluation of novel rapid detection kits for dengue virus NS1 antigen in Dhaka None. None.